Literature DB >> 19390209

Cardiorenal risk prevalence in sickle cell hemoglobinopathy.

H Abo-Zenah1, M Moharram, A M El Nahas.   

Abstract

INTRODUCTION: The spectrum of kidney functional and structural alterations in sickle cell hemoglobinopathy (SCH) is broad. Also, morbidity and mortality from end organ dysfunction, especially cardiorenal dysfunction, are substantial. Consequently, screening an SCH population prospectively for surrogate markers of cardiorenal risk such as albuminuria and intima-media thickness (IMT) was the aim of this cross-sectional study. PATIENTS AND METHODS: We screened 165 patients with SCH over 4 months at the Primary Care Department, King Abdulaziz Armed Forces Hospital, Saudi Arabia. The 133 who fulfilled the inclusion criteria have been referred for further investigations. Anthropometric evaluation of body mass index (BMI) and blood pressure (BP), determination of 24-hour urine albuminuria, fasting lipids, computed atherogenic risk ratio (ARR), estimated glomerular filtration rate (eGFR), common carotid artery (CCA) IMT measurements, and hemoglobin (Hb) electrophoresis were done.
RESULTS: Increased urinary albumin excretion (UAE) rate [380 (272.2-489.6) mg/day; mean and 95% confidence interval (95% CI) of mean] was detected in 24% of SCH patients (6 males and 26 females). Microalbuminuria (168.8 +/- 59.7 mg/day) was noted in the majority (63.6%) while macroalbuminuria (752.7 +/- 205.4 mg/day) was detected in a smaller percentage (36.4%). Patients with sickle cell disease (SCD) contributed about 66.6% of subjects with microalbuminuria and 100% of those with macroalbuminuria, while most individuals with sickle cell trait (89%) were normoalbuminuric (p < 0.0001). Preclinical atherosclerosis (increased CCA IMT and/or atheromatous plaques) was noticed in 68.8% of SCH individuals with increased UAE (ANOVA p = 0.003). The microalbuminuric and macroalbuminuric patients had comparable BMI, BP values and lipid profiles. However, the microalbuminuric sicklers were significantly younger (28.4 +/- 6.7 vs. 34.0 +/- 7.2 years, p = 0.04), less anemic (Hb: 9.13 +/- 2 vs. 7.47 +/- 0.8 g/dl, p = 0.015), with lesser atherosclerosis (IMT; 0.68 +/- 0.1 vs. 0.78 +/- 0.1 mm, p = 0.004) and higher eGFR (83.3 +/- 17.2 vs. 61 +/- 10.7 ml/min/1.73 m(2), p = 0.0004) compared to those with macroalbuminuria. UAE correlated positively with age (r = 0.591, p = 0.0001), systolic BP (r = 0.483, p = 0.005), IMT (r = 0.399, p = 0.024) and negatively with Hb (r = -0.409, p = 0.02), and eGFR (r = -0.620, p = 0.0001). By univariate analysis, the significant indicators of UAE in SCH patients were age (p = 0.05), BMI (p = 0.041), IMT (p = 0.018) and eGFR (p = 0.016). Also, increased risk (odds ratio) of albuminuria was noted with SCD, age, anemia, abnormal eGFR, obesity, and ARR.
CONCLUSIONS: Markers of cardiorenal risk such as albuminuria and IMT are common findings in SCH patients of Arabic descent and could be useful screening tools to identify sicklers at risk for cardiovascular and renal events. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19390209     DOI: 10.1159/000213897

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  6 in total

1.  Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon.

Authors:  Amy Geard; Gift D Pule; Bernard Chetcha Chemegni; Valentina J Ngo Bitoungui; Andre P Kengne; Emile R Chimusa; Ambroise Wonkam
Journal:  Br J Haematol       Date:  2017-05-03       Impact factor: 6.998

2.  Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia.

Authors:  Santosh L Saraf; Xu Zhang; Tamir Kanias; James P Lash; Robert E Molokie; Bharvi Oza; Catherine Lai; Julie H Rowe; Michel Gowhari; Johara Hassan; Joseph Desimone; Roberto F Machado; Mark T Gladwin; Jane A Little; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2013-12-12       Impact factor: 6.998

3.  Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent.

Authors:  Geraldo B Silva Junior; Ana Patrícia F Vieira; Amanda X Couto Bem; Marília P Alves; Gdayllon C Meneses; Alice M C Martins; Sonia M H A Araújo; Alexandre V Libório; Elizabeth F Daher
Journal:  Int J Clin Pharm       Date:  2014-06-17

4.  All-Cause Mortality and Incidence of Major Adverse Cardiac Events in Sickle Cell Nephropathy: A Comparative Study.

Authors:  Kunjan Udani; Nayda Parisio-Poldiak; Julia Campbell; Victor Collier; Pooja Patel
Journal:  Cureus       Date:  2021-05-16

5.  Prevalence and determinants of microalbuminuria in children suffering from sickle cell anemia in steady state.

Authors:  Michel N Aloni; Jean-Louis L Mabidi; René M Ngiyulu; Pépé M Ekulu; Fiston I Mbutiwi; Jean Robert Makulo; Ernest K Sumaili; Jean Lambert Gini-Ehungu; Célestin N Nsibu; Nazaire M Nseka; François B Lepira
Journal:  Clin Kidney J       Date:  2017-07-12

6.  Comparison of patients from Nigeria and the USA highlights modifiable risk factors for sickle cell anemia complications.

Authors:  Titilola S Akingbola; Bamidele O Tayo; Babatunde Salako; Jennifer E Layden; Lewis L Hsu; Richard S Cooper; Victor R Gordeuk; Santosh L Saraf
Journal:  Hemoglobin       Date:  2014-06-18       Impact factor: 0.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.